Form 4: SOPHiA GENETICS CEO Sells Shares Under 10b5-1 Plan

SOPHiA GENETICS SA CEO Jurgi Camblong reports sales of company shares totaling over 12,000 units, executed under a pre-arranged trading plan.

Summary

• Jurgi Camblong, CEO of SOPHiA GENETICS SA, reported the sale of 8,500 ordinary shares on April 10, 2026, at a weighted average price of $4.718.
• An additional 3,732 ordinary shares were sold on April 10, 2026, also at a weighted average price of $4.718.
• On April 13, 2026, 4,399 ordinary shares were sold at a weighted average price of $4.7641.
• These transactions were conducted under a Rule 10b5-1(c) trading plan, indicating they were pre-arranged and not discretionary.
• The sales were partly to cover tax withholding obligations related to restricted stock unit vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions were conducted under a pre-arranged trading plan (Rule 10b5-1) and appear to be for tax withholding purposes, which are routine for executives.

Negatives

• CEO Jurgi Camblong sold a total of 16,631 shares across April 10th and 13th, 2026.
• The sales occurred at weighted average prices between $4.60 and $4.88, indicating a disposition of company stock by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this filing, which is a statement of changes in beneficial ownership.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan is common practice for executives to sell shares in an orderly manner while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a trading plan, may be perceived negatively by some investors, although the plan's existence mitigates concerns about opportunistic selling.
• Employees: The sales, particularly those for tax withholding, highlight the financial obligations associated with equity compensation, which can be a factor for employee understanding of their own compensation packages.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CEO, Jurgi Camblong, Securities and Exchange Commission